Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs.
With a successful history in pharmaceutical sales and marketing and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects using a repurposing and reformulation strategy.
It has two late-stage clinical phase products under development, Nefecon® and Busulipo™, having successfully divested its Xepol® product in 2010.
In addition to driving its existing products towards commercialisation, Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications.
Link to corporate leaflet.